Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update

Joint Bone Spine

Volumn 74, Issue 6, 2007, Pages 638-646

  Pham, Thao ^a   Fautrel, Bruno ^b   Dernis, Emmanuelle ^c   Goupille, Philippe ^d   Guillemin, Francis ^e   Le Loët, Xavier ^f   Ravaud, Philippe ^g   Claudepierre, Pascal ^h   Miceli Richard, Corinne ⁱ   de Bandt, Michel ^j   Breban, Maxime ^k   Maillefert, Jean Francis ^l   Masson, Charles ^m   Saraux, Alain ⁿ   Schaeverbeke, Thierry ^o   Wendling, Daniel ^p   Mariette, Xavier ⁱ   Combe, Bernard ^q  

^a Rheumatology Department   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Hospital Center   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j Centre Hospitalier Robert Ballanger CHRB   (France)

^k CHU Ambroise Pare   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ SERVICE DE RHUMATOLOGIE   (France)

^o HÔPITAL PELLEGRIN   (France)

^p UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^q LAPEYRONIE HOSPITAL   (France)

more..

Author keywords

Ankylosing spondylitis; Clinical practice; Guidelines; Psoriatic arthritis; Therapy; TNF antagonists

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADJUSTMENT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; EXTERNAL VALIDITY; FOLLOW UP; HUMAN; INFLAMMATION; INTERNAL VALIDITY; LITERATURE; MEDICAL DOCUMENTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PHYSICIAN; PSORIATIC ARTHRITIS; REDUCTION; REMISSION; RHEUMATOLOGY; SACROILIAC JOINT; SPINE; STANDARD; STRUCTURE ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; X RAY FILM;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FRANCE; HEALTH STATUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36849016433     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.10.003     Document Type: Article

References (56)

1. Pham T., Guillemin F., Claudepierre P., Luc M., Miceli-Richard C., Fautrel B., et al. TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 73 (2006) 547-553
2. Shekelle P.G., Ortiz E., Rhodes S., Morton S.C., Eccles M.P., Grimshaw J.M., et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?. JAMA 286 (2001) 1461-1467
3. ANAES. Les recommandations pour la pratique clinique. Bases de la méthodologie pour leur réalisation en France (1999). www.anaes.fr
4. Shekelle P., Eccles M.P., Grimshaw J.M., and Woolf S.H. When should clinical guidelines be updated?. BMJ 323 (2001) 155-157
5. Shekelle P.G., Woolf S.H., Eccles M., and Grimshaw J. Clinical guidelines: developing guidelines. BMJ 318 (1999) 593-596
6. van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984) 361-368
7. Wendling D. Ankylosing spondylitis without radiological sacroiliitis: a (re)current problem. Joint Bone Spine 2006 73 (2006) 584-586
8. Wendling D., Toussirot E., Streit G., and Prati C. Imaging study scores for ankylosing spondylitis. Joint Bone Spine 73 (2006) 655-660
9. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
10. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
11. Chen J., and Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 3 (2004) CD004524
12. Dougados M., Dijkmans B., Khan M., Maksymowych W., van der Linden S., and Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61 Suppl. 3 (2002) 40-50 iii
13. Clegg D.O., Reda D.J., and Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42 (1999) 2325-2329
14. Schmidt W.A., Wierth S., Milleck D., Droste U., and Gromnica-Ihle E. Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. Z Rheumatol 61 (2002) 159-167 [in German]
15. Braun J., Zochling J., Baraliakos X., Alten R., Burmester G., Grasedyck K., et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65 (2006) 1147-1153
16. Haibel H., Rudwaleit M., Braun J., and Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64 (2005) 124-126
17. Van Denderen J.C., Van der Paardt M., Nurmohamed M.T., de Ryck Y.M., Dijkmans B.A., and van der Horst-Bruinsma I. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 64 (2005) 1761-1764
18. Haibel H., Brandt H., Song I.H., Brandt A., Listing J., Rudwaleit M., et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label study. Ann Rheum Dis 66 (2007) 419-421
19. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., and Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13 (1995) 589-593
20. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50 (2004) 1939-1950
21. Combe B., Goupille P., Kuntz J.L., Tebib J., Liote F., and Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 35 (1996) 664-668
22. Fraser A.D., van Kuijk A.W., Westhovens R., Karim Z., Wakefield R., Gerards A.H., et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64 (2005) 859-864
23. Sarzi-Puttini P., Cazzola M., Panni B., Turiel M., Fiorini T., Belai-Beyene N., et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 21 (2002) 234-238
24. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28 (2001) 2274-2282
25. Tubach F., Salmon D., Lemann M., Chichemanian R.M., Alili F., Benammar N., et al. Le risque tuberculeux persiste chez les patients traités par anti-TNFa. Identification des facteurs de risque chez ces patients. Rev Rhum 73 (2006) 1028
26. Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl. 3 (2005) S194-S198
27. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
28. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36 (2006) 159-167
29. Braun J., Baraliakos X., Listing J., Davis J., van der Heijde D., Haibel H., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57 (2007) 639-647
30. Gladman D.D., Mease P.J., Ritchlin C.T., Choy E.H., Sharp J.T., Ory P.A., et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56 (2007) 476-488
31. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
32. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
33. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64 (2005) 1150-1157
34. Cherouvim E.P., Zintzaras E., Boki K.A., Moutsopoulos H.M., and Manoussakis M.N. Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment. J Clin Rheumatol 10 (2004) 162-168
35. Kavanaugh A., Krueger G.G., Beutler A., Guzzo C., Zhou B., Dooley L.T., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through one year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66 (2007) 498-505
36. Breban M., Ravaud P., Claudepierre P., Baron G., Hudry C., Euller-Ziegler L., et al. No superiority of infliximab (INF) + methotrexate over INF alone in the treatment of ankylosing spondylitis: results of a one-year randomized prospective study. Arthritis Rheum 52 (2005) S214
37. Kinney T., Rawlins M., Kozarek R., France R., and Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98 (2003) 608-612
38. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 711-715
39. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 921-926
40. de Vries M.K., Wolbink G.J., Stapel S., de Vrieze H., Van Denderen J.C., Dijkmans B.A., et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66 (2007) 1252-1254
41. van der Heijde D., Bellamy N., Calin A., Dougados M., Khan M.A., and van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24 (1997) 2225-2229
42. van der Heijde D., Calin A., Dougados M., Khan M.A., van der Linden S., and Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 26 (1999) 951-954
43. Gladman D.D. Consensus exercise on domains in psoriatic arthritis. Ann Rheum Dis 64 Suppl. 2 (2005) 113-114 ii
44. Maksymowych W.P., Jhangri G.S., Lambert R.G., Mallon C., Buenviaje H., Pedrycz E., et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29 (2002) 959-965
45. Sidiropoulos P., Kritikos H.D., Siakka P., Mamoulaki M., Kouroumali H., Voudouris K., et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23 (2005) 513-516
46. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
47. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
48. Delaunay C., Farrenq V., Marini-Portugal A., Cohen J.D., Chevalier X., and Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 32 (2005) 2183-2185
49. Cantini F., Niccoli L., Benucci M., Chindamo D., Nannini C., Olivieri I., et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 55 (2006) 812-816
50. Durieux P., Ravaud P., Dosquet P., and Durocher A. Mise en oeuvre des recommandations médicales: revue systématique des revues systématiques. Gastroenterol Clin Biol 24 (2000) 1018-1025
51. Gossec L., Kvien T., Phillips C., Hammoudeh M., de Vlam K., Pavelka K., et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 66 suppl 11 (2007) 65
52. Keat A., Barkham N., Bhalla A., Gaffney K., Marzo-Ortega H., Paul S., et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 44 (2005) 939-947
53. Maksymowych W.P., Inman R.D., Gladman D., Thomson G., Stone M., Karsh J., et al. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 30 (2003) 1356-1363
54. Braun J., Pham T., Sieper J., Davis J., van der Linden S., Dougados M., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
55. Braun J., Davis J., Dougados M., Sieper J., van der Linden S., and van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 316-320
56. Durieux P., Ravaud P., Chaix C., and Durand-Zaleski I. La formation médicale continue améliore-t-elle le comportement des médecins?. Presse Med 28 (1999) 468-472